The rare disorder Duchenne muscular dystrophy is treated with genetic medicines that get skeletal muscle cells to produce a version of the key protein that they lack. Though these therapies slow ...

NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting ...

Recent research from the University of Houston College of Pharmacy identifies key mechanisms of skeletal muscle regeneration and growth of muscles following resistance exercise. It's a finding that ...

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater ...

Researchers have identified a protein that’s critical to the development of skeletal muscle mass and strength and the tissue’s ability to metabolize glucose. They say their findings may lead to ...

The Company’s lead candidate, EDG-5506, an investigational orally administered small molecule designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in ...

University of Delaware’s Mona Batish is a molecular biologist. She studies circular RNAs formed as a result of so-called molecular mistakes that occur when a strand of RNA — the ribonucleic acid that ...

The resubmission follows the positive results from the HOPE-3 Phase 3 trial. ・The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of Aug. 22, 2026. ・The investigational therapy ...

The MarketWatch News Department was not involved in the creation of this content. -- NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in ...